Fitusiran, an experimental hemophilia therapy administered through a monthly subcutaneous injection, met its primary endpoint in a phase III trial being presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. The drug dramatically reduced bleeding events, with half of those receiving it experiencing no bleeds and 85% experiencing an annualized bleed rate of three or fewer bleeds over the study period of about eight months. Dr. Alok Srivastava (Batch 1976) presented finds of this new study at the conference on December 14th, 2021. Read more here.
CMC Alumni in the News
Dr. Alok Srivastava Presents a Promising Experimental Hemophilia Therapy at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
Other Alumni in the News
Dr. Preman Singh (MBBS batch of 1983) Awarded the Peter Beaconsfield Runner-up Prize in Molecular Genetics at Oxford University in the Department of Physiology, Anatomy and Genetics (DPAG).
The Wilson Group – the assessors of the Peter Beaconsfield Prize have awarded Dr. Preman Singh the £250 Runner-up Prize. The prize is intended to reward young researchers who are
Richard Lane from The Lancet profiles Dr. Gagandeep Kang, leading virologist, Professor of Microbiology, Wellcome Trust Lab at CMC and co-chair of the Lancet Citizen’s Commission on Reimagining India’s Health
Dr. Vincent Rajkumar (Batch ’84) Receives the Prestigious 2021 Waldenström Award by the International Myeloma Society
The Waldenström Award is given by the International Myeloma Society to outstanding researchers in recognition of their contributions to the myeloma field. Read more here.
STAY IN TOUCH
Sign up for our Newsletter